A shipment marked “Detained” on a Notice of FDA Action has not yet been refused. The notice generally gives 20 calendar days from detention to send evidence or ask to recondition the product. Lab results may support release of one entry, but getting off the FDA import alert takes a petition showing the cause is fixed.
I chair the Customs and Trade Practice at OFW Law, where my work includes import alert removals and responses to Notices of FDA Action. I wrote this guide with J. Mason Weeda, the firm’s Managing Principal and Chair of its FDA Food Practice and Digital Health Practice.
What the Notice of FDA Action and Your Listing Mean
A Notice of FDA Action marked “Detained” serves as FDA’s Notice of Detention and Hearing, and it must state the reasons. Not every detention comes from an import alert. A Customs and Border Protection (CBP) hold is a separate matter, which our article on goods detained by customs covers.
If an FDA import alert is behind the detention, the product is already listed for detention without physical examination (DWPE). FDA can then hold later shipments without testing them. A listed firm then has two jobs, answering each detention and petitioning for removal, which has its own section below.
The list of FDA import alerts sits in databases FDA updates in real time, searchable by keyword or by country or area. Without double quotes around a phrase, the search matches each word separately. The published listing is usually FDA’s notice to the firm.
The Red List holds firms, products or countries that have met the criteria for DWPE under an alert. The Green List holds those that have met the criteria for exemption from DWPE under that alert. Firms left off a Green List stay subject to DWPE.
Each alert calls itself guidance that “does not operate to bind FDA or the public.” FDA’s import alerts page treats firms on an alert’s Yellow or Red List as subject to DWPE under that alert. Under Import Alert 21-11, which covers ackees, a Yellow-listed firm may export and provide private lab results to release each shipment.
Listings rest on section 801(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act). FDA calls this authority the “appearance standard.” The test is whether it “appears from the examination of such samples or otherwise” that an article is violative.
FDA’s Regulatory Procedures Manual (RPM), Chapter 9, binds neither FDA nor the public. Written for FDA staff, it says a listing may rest on the violative history of a product, firm, area or country. One violative sample may support DWPE when the violation is a potentially significant health hazard.
The Response Window and Who May Answer
Under 21 CFR 1.94, the notice must set a place and a period for testimony, but the rule fixes no number of days. FDA’s Detention and Hearing page supplies the numbers. The RPM allows 10 business days from detention, and the notice generally gives 20 calendar days to allow for weekends, holidays and mailing.
- Note both dates on the notice, the date of detention and the response period.
- Contact the compliance officer listed on the last page of the notice with questions. The same officer is generally the hearing officer.
- Decide who will respond. The importer of record may be the broker, consignee, owner or whoever owns the bond covering the shipment. A designated representative may also respond with written authorization from the consignee, owner or importer.
- Ask for any extension inside the period, with a reasonable basis. If FDA grants one, the new period should appear on a new Notice of FDA Action. The RPM says extensions for indefinite or excessively long periods should not be granted.
- Upload documents through the Import Trade Auxiliary Communication System (ITACS), which FDA names as its preferred method.
A missed window, with no extension asked for or granted, is one ground FDA lists for refusal. A detention can also be appealed, including to the Center responsible for the product. While the importer’s appeal is pending, the RPM tells FDA staff not to issue a Notice of FDA Action refusing the shipment.
How Testimony, Laboratory Analysis and Reconditioning Differ
Start with the alert’s Guidance section, which says whether the violation rules out release. If release is possible, testimony is evidence that the product does not have the violation FDA cites. Reconditioning instead offers a plan to bring the product into compliance.
Testimony can be any information sent to overcome the appearance of the violation or to support release. The owner or consignee has a legal right to offer it. Under 21 CFR 1.94 it may be oral or written, if it bears on admissibility.
Private lab results are one form of testimony. Depending on the violation, a private lab may sample and test a product under DWPE to give evidence against the apparent violation. FDA reviews these lab packages under Compliance Policy Guide 150.200.
For food, tests for admission and a run of passing tests offered to support removal fall under FDA’s lab accreditation rule, LAAF. Once an analyte’s compliance date passes, only a LAAF-accredited lab may do them. Mycotoxins reached that date on December 1, 2024, and FDA posts other analytes on its LAAF Dashboard as capacity allows.
The law itself makes room for reconditioning. Section 801(a) says covered articles “shall be refused admission, except as provided in subsection (b) of this section.” Subsection (b) lets FDA allow relabeling or other steps that bring some articles, such as adulterated or misbranded ones, into compliance.
Under 21 CFR 1.95, the application “may be filed only by the owner or consignee.” The owner or consignee is the importer of record, who sends Form FDA 766 to the compliance officer on the notice. The application must contain detailed proposals for bringing the product into compliance.
Under the RPM, a designated agent, such as a customhouse broker or consultant, may apply for a bonded owner or consignee. FDA may grant or deny the application, and the owner or consignee pays for FDA’s supervision at hourly rates set in 21 CFR 1.99. FDA’s import refusals page says a third try will generally not be granted.
Why Clearing Shipments One by One Does Not End the Listing
Brokers and labs can carry real parts of this work. The importer of record may be the broker, and in that role a broker can answer the notice or file for reconditioning. A lab’s analysis can supply the evidence for release.
An entry released on evidence still leaves the firm or product on the FDA import alert. Under DWPE, each later shipment is detained and refused unless the importer overcomes the appearance of the violation. Some alerts rule out release or list violations that “may require corrective action and removal from DWPE to secure a release of the shipment.”
FDA’s own manual is plain about where that leaves the importer. DWPE “properly places the responsibility for ensuring compliance with the law on the importer,” in the manual’s words. The same section also says that “FDA is a regulatory agency, not a quality control laboratory.”
FDA’s removal table and the RPM point to a root cause, corrective actions and, where required, a run of routine commercial entries. Once the manufacturer is known, the RPM expects it, not the shipper, to send that evidence. The whole record has to show FDA that the conditions behind the listing are resolved and that later shipments will comply.
Building an FDA Import Alert Removal Petition
FDA’s removal page says FDA weighs all the evidence together. The core is evidence “that the conditions that led to DWPE have been resolved” and that later shipments will be safe and compliant. Contents may vary by alert, product, problem and type of removal, and for a Red List the page’s table frames four elements as questions.
- Investigation. How did the problem occur in the product?
- Corrective actions. What was done to fix it?
- Preventive measures. What keeps it from happening again?
- Evidence. What shows those measures are working? FDA’s examples include five clean shipments and a third-party audit.
The RPM says FDA may require a root cause analysis and a description of corrective actions. Some products are listed because the country where they were made or shipped from bans or limits their sale. For those, FDA may require proof that the ban or limit has ended.
An inspection-based listing may need a new inspection first. Depending on the violation, FDA may also need a registration, a scheduled process filing, or a premarket clearance or approval. The RPM names a 510(k) substantial equivalence order, premarket approval application (PMA), NDA and NADA among them.
FDA’s removal page speaks to the petitioner directly, and the Guidance section of an FDA import alert can also say who may file. Import Alert 21-11 takes petitions from “a firm and/or a representative thereof.” The foreign supplier verification alert, 99-41, takes requests from “the importer or representative thereof,” sent to the office that issued the importer’s regulatory letter.
As of October 2026, FDA’s import contact page lists [email protected] for removal requests. The removal page sends petitions there too, unless the alert’s Guidance section names the division compliance officer. The updated alert is usually FDA’s notice of the removal.
Clean Shipment Benchmarks for Getting Off an FDA Import Alert
A run of five clean shipments is a common minimum, on top of corrective actions. Under the RPM, a listing for an adulterated or misbranded product may require “a minimum of five (5) consecutive non-violative commercial shipments.” Some cases may need more, such as a firm that resumes violative shipments after removal.
Under the RPM, splitting a shipment into several entries or lines should not be used to raise the count of clean shipments. Loads under 10 to 15 cartons may be disregarded unless that is normal for the product. Shipments should reflect normal shipping patterns.
FDA’s FAQ gives no set number for “routine commercial entries” and no exact span for a “reasonable time period.” The March 2024 edition of Chapter 9 sets a separate benchmark for each type of listing, from one maker’s products to repeat importers.
| Type of listing | Clean record the RPM describes |
|---|---|
| Specific products from one manufacturer (fresh produce excluded) | The last five shipments documented in compliance |
| Multiple products from one manufacturer | The last 12 shipments non-violative |
| A product from a country or geographic area | The last 12 shipments non-violative, including a representative number of manufacturers or shippers |
| A grower listed for illegal pesticide residues on fresh produce | At least five consecutive recent shipments without violation, plus one of four documentation conditions |
| A shipper | Six months with no violative shipment offered for entry, plus documentation of preventive steps |
| An importer, first listing | The last five shipments of one product from one manufacturer in full compliance, or 12 for multiple products |
| An importer, repeat listing | The 10 most recent entries for one product, or the last 24 for multiple products, in full compliance |
| An inspection or GMP listing | Reinspection is the general route, sometimes by a reliable third party, with Center concurrence. Documentation alone may sometimes suffice. |
Some FDA import alerts set their own path in the Guidance section. Import Alert 21-11, covered in our article on ackee imports, is one example. To petition for that alert’s Green List, a Yellow-listed ackee firm documents at least five consecutive entries released on private laboratory analyses.
Questions About Detention, Refusal and Removal
How do I get removed from an FDA import alert?
By petition to FDA, with evidence that the cause of the listing is resolved. FDA requires no specific evidence if the firm no longer makes the product. For a grower listed for pesticide residues on produce, FDA or another interested party may recommend removal, the RPM says.
How does Red List removal differ from Green List addition?
FDA’s removal page treats them as separate types of removal, “remove from red” and “add to green,” each with evidence that may differ. For Green List addition, its table lists analysis, preventive measures and evidence. The lists differ too, one for DWPE and one for exemption from it.
What happens after an FDA import refusal?
The shipment must be destroyed or exported under CBP and FDA supervision within 90 days of the refusal notice. FDA cannot extend that period, and CBP may assess liquidated damages against the bond if the product is not returned in time. A refusal stays final unless FDA issued it in error.
Refused drugs, devices and tobacco products valued at $2,500 or less may be destroyed without the chance to export. The rule applies only if the article was not brought into compliance under section 801(b). Treasury may also set a higher dollar amount by regulation.
Is an FDA import detention the same as administrative detention?
No, administrative detention is a separate power from detention at import, under section 304(h) of the FD&C Act. Section 304(h) reaches food FDA finds during an inspection, examination or investigation. FDA must have reason to believe the food is adulterated or misbranded.
The hold may last up to 20 calendar days, or up to 30 when FDA needs the time to bring a seizure or injunction. An appeal is due within 2 calendar days for perishable food and within 10 for other food.
Is a prior notice refusal handled the same way?
No, it is its own ground for refusal, under section 801(m)(1). Section 801(m)(1) reaches food arriving without a confirmed prior notice, except international mail and food a person carries. Clearing that refusal does not settle admission under other rules, and our guide to importing human food explains how prior notice works.
Can a name or ownership change affect an import alert listing?
It can. FDA lists a new company name, owner or location among changes in conditions that may affect a firm’s status on an FDA import alert. Firms should send notice and documentation to FDA’s Division of Import Operations at [email protected].
Talk to OFW Law About a Notice or a Listing
Whether you are answering a Notice of FDA Action now or have just found your firm on an FDA import alert, start with OFW Law. Our food distribution and international trade practice helps importers respond to FDA detention notices, import alerts and refusals of admission. Ask for me, Denise Calle, or for Mason Weeda.


